EHA-SWG MPN Annual Report 2017

MAIN SECTIONS (NOTE: sections 1-4 will be used for publication on EHA website)

1. Name of the SWG: MYELOPROLIFERATIVE NEOPLASMS

2. Focus and mission of the SWG (this section will be published also as SWG short presentation on the EHA website)

The aims of the SWG are furthering collaboration and sharing knowledge between centres involved in the management of MPN, a focus to develop centres and clinicians who would be willing to host visiting staff for sabbaticals or learning experiences was agreed as well as a proposal to encourage presentations from junior staff. During the course of the year the SWG has also supported the development of a patient advocacy group network across the EU for patients with MPNs

3. SWG highlights of past calendar year

• The MPN SWG organized in October 2017 an educational meeting focusing on "Challenges in the diagnosis and management of Myeloproliferative Neoplasms". This meeting aimed at better identifying key clinical and scientific advances in MPN, facilitating collaboration between clinical and scientific MPN communities, encouraging the development of young scientists and clinicians in this field, and to engage with the patient community regarding models of care, advocacy and scientific research. • The MPN SWG also organized a tutorial on "Biology and management of myeloid malignancies" in Yerevan in collaboration with the Armenian Hematology Association. • In collaboration with the MPN group in Israel to a third practice survey regarding Ruxolitinib therapy in MF was undertaken and published.

4. Chair and affiliations:
   Professor Jean-Jacques Kiladjian
   Hôpital Saint-Louis and Paris Diderot University, Paris, France

   Professor Claire Harrison
   Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK

5. Board members and terms:
   Prof A. Almeida, Portugal
   Prof C. Besses, Spain

Prof S. Constantinescu, Belgium
Prof T. Devos, Belgium
Prof M. Ellis, Israel
Prof S. Giraudier, France
Prof M. Greisshamer, Germany
Prof H. Hasselbach, Denmark
Prof R. Kralovics, Austria
Prof M.F. McMullin, N. Ireland
Prof J. Samuelsson, Sweden
Prof J. Schwarz, Czechia
Prof R. Skoda, Switzerland
Prof A Vannucchi, Italy
Prof M. Wondergem, Netherlands
Prof L.Y. Shih, Taiwan

6. Conflicts of interest of the board: none

7. Membership list with names and email addresses:

Prof A. Almeida, Portugal	amalmeida@ipolisboa.min-saude.pt
Prof C. Besses, Spain	92717@parcdesalutmar.cat
Prof S. Constantinescu, Belgium	stefan.constantinescu@bru.licr.org
Prof T. Devos, Belgium	Timothy.Devos@uzleuven.be
Prof M. Ellis, Israel	docmartellis@gmail.com
Prof S. Giraudier, France	stephane.giraudier@aphp.fr
Prof M. Greisshamer, Germany	Martin.Griesshammer@muehlenkreiskliniken.de
Prof H. Hasselbach, Denmark	hans.hasselbalch@dadlnet.dk
Prof R. Kralovics, Austria	robert.kralovics@meduniwien.ac.at
Prof M.F. McMullin, N. Ireland	m.mcmullin@qub.ac.uk
Prof J. Samuelsson, Sweden	jan.samuelsson@sodersjukhuset.se
Prof J. Schwarz, Czechia	jiri.schwarz@uhkt.cz
Prof R. Skoda, Switzerland	radek.skoda@unibas.ch
Prof A Vannucchi, Italy	a.vannucchi@unifi.it
Prof M. Wondergem, Netherlands	M.Wondergem@vumc.nl
Prof L.Y. Shih, Taiwan	sly7012@cgmh.org.tw

8. List of scientific activities

- The SWG session at the EHA 2017 meeting was well attended
- An educational SWG meeting took place in 2017
- The SWG also supported an EHA tutorial in Armenia

- In collaboration with the MPN group in Israel to a third practice survey regarding Ruxolitinib therapy in MF was undertaken and published
- Collaboration to prospectively survey aspirin and thrombosis in CALR positive patients – submitted and published
- For the second a pan EU patient advocacy group met in Frankfurt this was supported by Prof Harrison, Ellis, McMullin and Griesshammer
- "MEASURES study" a quality of life assessment study without an investigation medical product. This support was launched at the 2014 meeting and is on-going and recruiting well.

- First line PV study, is progressing to final contract stage.

9. List of publications from or related to the SWG

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.
Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN.
Leuk Res. 2017 Oct;61:6-9. doi: 10.1016/j.leukres.2017.08.002. Epub 2017 Aug 10